Exhibit 99.1 | --- | --- | --- | --- | |-------------------|----------------------------------|----------------------|-----------------------------------| | | | | | | | | | | | Media Contacts: | Karissa Peer | Investor Contacts: | Jennifer Halchak | | | (614) 314-8094 Kate Vossen | | (201) 275-2711 Renee McKnight | | | (732) 675-8448 | | (551) 204-6129 | Organon Reports Results for the Third Quarter Ended September 30, 2024 · Third quarter 2024 revenue of $1.582 billion, up 4% as-reported and up 5% at const ...

Core Viewpoint - Organon's upcoming quarterly earnings report is anticipated to show a slight decline in earnings per share but a modest increase in revenue compared to the previous year [1] Financial Performance - Expected quarterly earnings of $0.85 per share, a decrease of 2.3% year-over-year [1] - Forecasted revenues of $1.56 billion, reflecting a year-over-year increase of 2.7% [1] - Analysts have revised the consensus EPS estimate upward by 1.1% over the past 30 days [1] Revenue Estimates by Segment - Revenue from Women's Health - Nexplanon/Implanon NXT is estimated at $238.19 million, indicating an 8.3% increase year-over-year [3] - Revenue from Women's Health - Follistim AQ is projected at $66.32 million, showing a 22.8% increase from the prior year [4] - Total revenue from Biosimilars is expected to reach $168.58 million, reflecting an 18.7% increase year-over-year [4] - Total revenue from Women's Health is estimated at $452.30 million, indicating an 8.2% increase from the previous year [5] - Revenue from Women's Health - U.S. - Nexplanon/Implanon NXT is projected at $164.46 million, a 12.6% increase year-over-year [5] - Geographic revenue from the U.S. is expected to be $400.64 million, reflecting an 8.3% increase from the prior year [6] - Revenue from Women's Health - U.S. - NuvaRing is expected to decline to $10.08 million, a decrease of 44% year-over-year [6] - Revenue from Women's Health - U.S. - Follistim AQ is projected at $25.52 million, indicating a 16% increase from the previous year [7] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Other is expected to be $69.71 million, a slight decrease of 0.4% year-over-year [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Diprospan is projected at $34.34 million, reflecting a 10.8% increase [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Fosamax is expected to be $35.27 million, a decrease of 11.8% year-over-year [9] Stock Performance - Over the past month, Organon's shares have declined by 10.5%, while the Zacks S&P 500 composite has increased by 2% [9] - Organon currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [9]

Organon (OGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 31, 2024, might help the stock move higher if these key numbers are better than exp ...

In the latest trading session, Organon (OGN) closed at $18.10, marking a +0.56% move from the previous day. This move lagged the S&P 500's daily gain of 0.77%. Elsewhere, the Dow saw an upswing of 0.47%, while the tech-heavy Nasdaq appreciated by 0.87%. The pharmaceutical company's stock has dropped by 12.07% in the past month, falling short of the Medical sector's loss of 3% and the S&P 500's gain of 4.87%. The upcoming earnings release of Organon will be of great interest to investors. The company's earni ...

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is o ...

In the latest market close, Organon (OGN) reached $18.58, with a -1.33% movement compared to the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Prior to today's trading, shares of the pharmaceutical company had lost 14.72% over the past month. This has lagged the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time. Analysts and investors alike will be keeping a close ey ...

In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Organon (OGN) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.72%, and the technology-centric Nasdaq increased by 0.65%. Shares of the pharmaceutical company witnessed a gain of 0.35% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The upcoming earn ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...